The place of sodium glucose co-transporter-2 inhibitors in the treatment of type 2 diabetes mellitus and its complications from the evidence-based medicine viewpoint


DOI: https://dx.doi.org/10.18565/therapy.2020.8.90-104

Demidova T.Yu., Alekseeva Ya.G.

1) N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 2) AO «Astellas Pharma», Moscow
Effective treatment of type 2 diabetes mellitus (DM) with a focus on the prevention of cardiovascular diseases (CVD) is becoming an increasingly urgent public health problem that requires multifactorial regulation of all cardiovascular risk factors, and not just the achievement of glycemic control. Inhibitors of sodium-glucose co-transporter 2 are an innovative class of antihyperglycemic medicines with a universal, evident and persistent hypoglycemic action, as well as numerous non-glycemic effects. Use of them opens up great perspectives not only in terms of improving glycemic control, but also in the prevention of micro- and macrovascular complications of type 2 diabetes melitus. This article presents the main advantages of this group of medicaments in type 2 diabetes melitus treatment, and also discusses strategies that can reduce the risk of CVD in this population.
Keywords: inhibitors of sodium-glucose co-transporter 2, type 2 diabetes mellitus, cardiovascular risk
Read entire article

Literature


  1. IDF Diabetes Atlas. 2017. 8th Edition. Available from: http://www.diabetesatlas.org/component/attachments/?task=download&id=254 (date of access – 01.12.2020].

  2. Дедов И.И., Шестакова М.В., Викулова О.К. с соавт. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018; 3: 144–159. [Dedov I.I., Shestakova M.V., Vikulova O.K. et al. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Sakharniy diabet. 2018; 3: 144–159 (In Russ.)]. doi: 10.14341/DM9686.

  3. Calderon-Larranaga A., Abad-Dieza G.M., Gimeno-Feliuet L.A. et al. Global health care use by patients with type-2 diabetes: Does the type of comorbidity matter? Eur J Intern Med. 2015; 26(3): 203–10. doi: 10.1016/j.ejim.2015.02.011.

  4. Nowakowska M., Zghebi S.S., Ashcroft D.M. et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019; 17(1): 145. doi: 10.1186/s12916-019-1373-y.

  5. Gaede P., Oellgaard J., Carstensen B. et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016; 59(11): 2298–2307. doi: 10.1007/s00125-016-4065-6.

  6. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск. Сахарный диабет. 2019; S1–1: 1–144. [Dedov I.I., Shestakova M.V., Mayorov A.Y. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Sakharniy diabet. 2019; S1–1: 1–144 (In Russ.)]. https://doi.org/10.14341/DM221S1

  7. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43(Suppl 1): S98–S110. doi: 10.2337/dc20-S009.

  8. Wan E.Y.F., Fung C.S.C., Jiao F.F. et al. Five-Year effectiveness of the multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) on diabetes-related complications and health service uses-a population-based and propensity-matched cohort study. Diabetes Care. 2018; 41(1): 49–59. doi: 10.2337/dc17-0426.

  9. Lim S., Eckel R.H., Koh K.K. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis. 2018; 272: 33–40. doi: 10.1016/j.atherosclerosis.2018.03.013.

  10. Cosentino F., Grant P.J., Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323. doi: 10.1093/eurheartj/ehz486.

  11. Kosiborod M., Cavender M.A., Fu A.Z. et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017; 136(3): 249–59. doi: 10.1161/CIRCULATIONAHA.117.029190.

  12. Kosiborod M., Lam C.S.P., Kohsaka S. et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018; 71(23): 2628–39. doi: 10.1016/j.jacc.2018.03.009.

  13. Birkeland K.I., Bodegard J., Banerjee A. et al. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab. 2021; 23(1): 75–85. doi: 10.1111/dom.14189.

  14. Handelsman Y. Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Adv Ther. 2019; 36(10): 2567–86. doi: 10.1007/s12325-019-01054-w.

  15. Deerochanawong C., Chan S.P., Matawaran B.J. et al. Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. Diabetes Obes Metab. 2019; 21(11): 2354–67. doi: 10.1111/dom.13819.

  16. Fonseca V.A., Ferrannini E., Wilding J.P. et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications. 2013; 27(3): 268–73. doi: 10.1016/j.jdiacomp.2012.11.005.

  17. Kashiwagi A., Kazuta K., Takinami Y. et al. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetol Int. 2015; 6(1): 8–18.

  18. Elgebaly A., Abdelazeim N., Abdelazeim B. et al. Tolerability and efficacy of ipragliflozin in the management of inadequately controlled type 2 diabetes mellitus: a systematic review and meta-analysis. Exp Clin Endocrinol Diabetes. 2018 Jun 18. doi: 10.1055/a-0579-7860.

  19. Kashiwagi A., Kazuta K., Goto K. et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2015; 17(3): 304–08. doi: 10.1111/dom.12331.

  20. Kashiwagi A., Akiyama N., Shiga T. et al. Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study. Diabetol Int. 2015; 6(2): 125–38.

  21. Kashiwagi A., Shiga T., Akiyamaet N. et al. Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). Diabetol Int. 2015; 6(2): 104–116.

  22. Kashiwagi A., Isaka H., Kawano H. Long-term safety, tolerability and efficacy of ipragliflozin in combination with a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus inadequately controlled with a dipeptidyl peptidase-4 inhibitor alone – DAYLIGHT Study. Jpn Pharmacol Ther. 2014; 42(12): 941–57.

  23. Lu C.H., Min K.W., Chuang L.M. et al. Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. J Diabetes Investig. 2016; 7(3): 366–73. doi: 10.1111/jdi.12422.

  24. Han K.-A., Chon S., Chung C.H. et al. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. Diabetes Obes Metab. 2018; 20(10): 2408–15. doi: 10.1111/dom.13394.

  25. Ishihara H., Yamaguchi S., Nakao I. et al. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab. 2016; 18(12): 1207–16. doi: 10.1111/dom.12745.

  26. Ishihara Н., Yamaguchi S., Nakao I., Sakatani T. Ipragliflozin add-on therapy to a GLP-1 receptor agonist in Japanese patients with type 2 diabetes (AGATE): A 52-week open-label study. Diabetes Ther. 2018; 9(4): 1549–67. doi: 10.1007/s13300-018-0455-8.

  27. Shestakova M.V., Wilding J.P.H., Wilpshaar W. et al. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018; 146: 240–50. doi: 10.1016/j.diabres.2018.10.018.

  28. Дедов И.И., Мельниченко Г.А., Шестакова М.В. с соавт. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-й пересмотр (Лечение морбидного ожирения у взрослых). Ожирение и метаболизм. 2018; 1: 53–70. [Dedov I.I., Melnichenko G.A., Shestakova M.V. et al. Russian National clinical recommendations for morbid obesity treatment in adults. 3rd revision (morbid obesity treatment in adults). Ozhirenie i metabolism. 2018; 1: 53–70 (In Russ.)]. DOI: 10.14341/OMET2018153-70.

  29. Hsia D.S., Grove O., Cefalu W.T. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017; 24(1): 73–79. doi: 10.1097/MED.0000000000000311.

  30. Nakamura I., Maegawa H., Tobe, K. et al. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in realworld clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. Expert Opin Pharmacother. 2018; 19(3): 189–201. doi: 10.1080/14656566.2017.1408792.

  31. Kawata T., Iizuka T., Iemitsu K. et al. Ipragliflozin improves glycemic control and decreases body fat in patients with type 2 diabetes mellitus. J Clin Med Res. 2017; 9(7): 586–95. doi: 10.14740/jocmr3038w.

  32. Koshizaka M., Ishikawa K., Ishibashi R. et al. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). Diabetes Obes Metab. 2019; 21(8): 1990–95. doi:10.1111/dom.13750.

  33. Reed J.W. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016; 12: 393–405. doi: 10.2147/VHRM.S111991.

  34. Kawasoe S., Maruguchi Y., Kajiya S. et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol. 2017; 18(1): 23. doi: 10.1186/s40360-017-0125-x.

  35. Filippatos T.D., Tsimihodimos V., Elisaf M.S. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opin Pharmacother. 2016; 17(12): 1581–83. doi: 10.1080/14656566.2016.1201073.

  36. Kashiwagi A., Yoshida S., Kawamuki K. et al. Effects of ipragliflozin, a selective sodium–glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, a placebo-controlled clinical trials. Diabetol Int. 2017; 8(1): 76–86. doi: 10.1007/s13340-016-0283-x.

  37. Farmer J.A. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Diab Rep. 2008; 8(1): 71–77. doi: 10.1007/s11892-008-0013-2.

  38. Кухарчук В.В., Ежов М.В., Сергиенко И.В. с соавт. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020; 1: 7–40. [Kukharchuk V.V., Ezhov M.V., Sergienko I.V. et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VII revision. Ateroskleroz i dislipidemiya. 2020; 1: 7–40 (In Russ.)]. doi: 10.34687/2219-8202.JAD.2020.01.0002.

  39. Inzucchi S.E., Zinman B., Wanner C. et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015; 12(2): 90–100. doi: 10.1177/1479164114559852.

  40. Kashiwagi A., Sakatani T., Nakamura I. et al. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials. Endocr J. 2018; 65(7): 693–705. doi: 10.1507/endocrj.EJ17-0491.

  41. Bando Y., Tohyama H., Aoki K., et al. Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus. J Clin Transl Endocrinol. 2016; 6: 1–7. doi:10.1016/j.jcte.2016.06.001.

  42. Lo K.В., Gul F., Ram P. et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: A systematic review and meta-analysis. Cardiorenal Med. 2020; 10(1): 1–10. doi: 10.1159/000503919.

  43. Zelniker T.A., Wiviott S.D., Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Lancet. 2019; 393(10166): 31–39. doi: 10.1016/S0140-6736(18)32590-X.

  44. 44. McGuire D.K., Shih W.J., Cosentino F. et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiol. 2020; e204511. doi: 10.1001/jamacardio.2020.4511.

  45. Arnett D.K., Blumenthal R.S., Albert M.A. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019; 140(11): e596–e646. doi: 10.1161/CIR.0000000000000678.

  46. Radholm K., Wu J.H., Wong M.G. et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. Diabetes Res Clin Pract. 2018; 140: 118–28. doi: 10.1016/j.diabres.2018.03.027.

  47. Abdelgadir E., Rashid F., Bashier A., Ali R. SGLT-2 inhibitors and cardiovascular protection: lessons and gaps in understanding the current outcome trials and possible benefits of combining SGLT-2 inhibitors with GLP-1 agonists. J Clin Med Res. 2018; 10(8): 615–25. doi: 10.14740/jocmr3467w.

  48. Dekkers C.C.J., Gansevoort R.T. Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease? Nephrol Dial Transplant. 2020; 35: i33–i42. doi: 10.1093/ndt/gfz264.

  49. Heerspink H.J.L., Kosiborod M., Inzucchi S.E., Cherney D.Z.I. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney International. 2018; 94; 26–39. doi: 10.1016/j.kint.2017.12.027.

  50. Matsuba I., Kawata T., Iemitsu K. et al. Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study. J Diabetes Investig. J Diabetes Investig. 2020; 11(5): 1248–57. doi: 10.1111/jdi.13248.

  51. Horii T., Oikawa Y., Kunisada N. et al. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study. BMJ Open Diabetes Research and Care. 2020; 8: e001856. doi: 10.1136/bmjdrc-2020-001856.

  52. Ueda P., Svanstrom H., Melbye M. et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018; 363: k4365. doi: 10.1136/bmj.k4365.

  53. Donnan J.R., Grandy C.A., Chibrikov E. et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019; 9(1): e022577. doi: 10.1136/bmjopen-2018-022577.

  54. Puckrin R., Saltiel M.P., Reynier P. et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018; 55(5): 503–14. doi: 10.1007/s00592-018-1116-0.

  55. Fadini G.P., Avogaro A. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System [published correction appears in Lancet Diabetes Endocrinol. 2018 Apr 13]. Lancet Diabetes Endocrinol. 2017; 5(9): 680–81. doi: 10.1016/S2213-8587(17)30257-7.

  56. Ryan P.B., Buse J.B., Schuemie M.J. et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes. Metab. 2018; 20: 2585–97. doi: 10.1111/dom.13424.


About the Autors

Tatyana Yu. Demidova, MD, professor, head of the Department of endocrinology, faculty of general medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 109263, Moscow, 4/1 Shkuleva Str. E-mail: t.y.demidova@gmail.com. ORCID: 0000-0001-6385-540X.
Yana G. Alekseeva, PhD, senior medical manager of AO «Astellas Pharma». Address: 109147, Moscow, 16 Marksistskaya Str. ORCID: http://orcid.org/0000-0002-5014-9239; eLibrary SPIN: 4954-0700


Similar Articles

Back to Content

Бионика Медиа